Surmodics, Inc. (NASDAQ:SRDX - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $38.60 and traded as high as $38.85. Surmodics shares last traded at $38.49, with a volume of 249,621 shares trading hands.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on SRDX shares. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Thursday. StockNews.com started coverage on Surmodics in a research report on Thursday. They set a "hold" rating for the company. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $50.00.
View Our Latest Report on Surmodics
Surmodics Stock Down 0.2 %
The firm's 50-day simple moving average is $38.62 and its 200 day simple moving average is $38.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. The stock has a market capitalization of $547.85 million, a P/E ratio of -384.90 and a beta of 1.20.
Institutional Trading of Surmodics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its position in shares of Surmodics by 7.5% during the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company's stock worth $202,000 after purchasing an additional 481 shares during the last quarter. SG Americas Securities LLC increased its holdings in Surmodics by 14.7% during the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company's stock worth $151,000 after buying an additional 660 shares during the last quarter. Vanguard Group Inc. increased its holdings in Surmodics by 0.7% during the first quarter. Vanguard Group Inc. now owns 865,214 shares of the company's stock worth $25,385,000 after buying an additional 5,927 shares during the last quarter. Acadian Asset Management LLC raised its position in Surmodics by 11.3% during the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company's stock worth $11,988,000 after acquiring an additional 41,617 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Surmodics in the first quarter valued at $1,270,000. Institutional investors own 96.63% of the company's stock.
Surmodics Company Profile
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Recommended Stories
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
